Five years after my lymphoma diagnosis, life looks normal on the outside; however, the fear of recurrence and the reality of ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in combination therapy.

CHICAGO — In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor ...

In July 2020, Monjuvi in combination with lenalidomide received FDA approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise ...

A new risk model uses objective clinical data to predict cure or relapse in Hodgkin lymphoma, with future plans to guide treatment and survivorship care.

Follicular lymphoma accounts for up to 30% of non-Hodgkin lymphoma (NHL) cases. Despite its slow progression, frequent relapses make long-term disease control a critical goal. Dr. Christina Poh ...

The Food and Drug Administration has approved an updated label for Amyvid (florbetapir F 18 injection) to support Alzheimer disease diagnosis in patients.

The authors concluded that PET and/or PET-CT were highly effective in detecting true recurrence in patients with suspicion of recurrent disease.